|
Healing at Home 2.0 - Enhanced Chat Tool for Lowering Postpartum Depression
RECRUITINGN/ASponsored by University of Pennsylvania
Actively Recruiting
PhaseN/A
SponsorUniversity of Pennsylvania
Started2025-03-13
Est. completion2026-02-28
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT06877104
Summary
The purpose of the study is to determine if access to a text-message based holistic chatbot support program "Healing at Home 2.0" decreases depressive symptoms as measured by the Edinburgh Postnatal Depression Scale (EPDS) compared to usual postpartum care for patients of color.
Eligibility
Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria: * Postpartum patients who have delivered a singleton baby at or after 37w0d at the Hospital of the University of Pennsylvania * Self-identify as a person of color (listed on chart as non-White race and confirmed with patient) * Able to speak, read and write English * Age ≥18 * Prenatal care at outpatient practice affiliated with the Hospital of the University of Pennsylvania * Completion of clinically administered EPDS during inpatient stay * Routine discharge timing, day 2 or more after vaginal delivery, day 3 or more after cesarean delivery Exclusion Criteria: * Unable to provide informed consent * Baby not discharged with mother at postpartum discharge * Does not have access to a mobile phone
Conditions3
DepressionDepression, PostpartumPostpartum Care
Locations1 site
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity of Pennsylvania
Started2025-03-13
Est. completion2026-02-28
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT06877104